NovaBay Pharmaceuticals Appoints Mark M. Sieczkarek Chairman

Announces Additional Changes to its Board of Directors

EMERYVILLE, Calif.--()--NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY), a biopharmaceutical company commercializing and developing topical non-antibiotic antimicrobial products for the global eye care market, announces the appointment of Mark M. Sieczkarek as Chairman of the Board, effective April 10, 2015. NovaBay founder Dr. Ron Najafi remains on the Board and continues to serve as NovaBay’s President and Chief Executive Officer. Mr. Sieczkarek has served as a director of NovaBay since January 2014.

“With an impressive background in ophthalmology and product launches, Mark Sieczkarek is ideally qualified to serve as our Board Chairman,” said Dr. Najafi. “Since joining our Board earlier this year, Mark has played an instrumental role in developing a well-conceived commercial strategy for Avenova™, our proprietary prescription product for the management of eye lid conditions. We are delighted by the market’s early acceptance of Avenova and will be looking for Mark’s continued guidance in supporting the success of NovaBay.”

“I’m extremely pleased to be named NovaBay’s Chairman at this exciting time as the Company transitions to a commercially focused eye-care entity,” said Mr. Sieczkarek. “I’m very impressed with the benefit Avenova brings patients who have suffered for years with blepharitis and dry eye. I look forward to contributing to this product’s success and advancing NovaBay’s overall business strategy.”

Mr. Sieczkarek was elected Chairman of Solta Medical, Inc. in June 2013, and in August 2013 was named interim President and Chief Executive Officer. He served in these positions until Solta Medical was acquired by Valeant Pharmaceuticals, Inc. in January 2014. Prior to Solta Medical, Mr. Sieczkarek was President and Chief Executive Officer of Conceptus, Inc., where he oversaw the successful commercial launch of the Essure® permanent birth control device. He previously was Senior Vice President and President of The Americas and Europe for the leading ophthalmic company Bausch & Lomb, Inc., with responsibility for commercial operation in the United States, Canada Latin America, Europe and Africa.

Additionally, NovaBay announces the appointment of Mr. LI Xinzhou (Paul Li) to the Board of Directors, also effective April 10, 2015. Mr. Li is Chairman, Executive Director of China Pioneer Pharma Holdings Limited, the exclusive distributor of NovaBay’s NeutroPhase® Skin and Wound Cleanser in China and Southeast Asia. Mr. Li has not been appointed to any committees and will not receive compensation for his Board membership. He will stand for re-election to the Board at NovaBay’s 2015 annual meeting of stockholders, which will be held June 12, 2015. Mr. Li’s appointment increases the size of the NovaBay Board to nine directors.

“I am delighted that Paul Li of China Pioneer Pharma, NovaBay’s largest shareholder, is joining the Board,” added Dr. Najafi. “Paul and his company have been tremendous supporters of NovaBay both as a distributor and as an investor. Paul has been our Board’s Asia-Pacific advisor for more than two years, providing his vision and strategic thinking for introducing NovaBay products into the China and Southeast Asia markets, as well as facilitating the collaboration between our companies.”

Mr. Li founded China Pioneer Pharma in July 1996, and is responsible for managing the operations and planning, and for formulating the company’s strategies. He has more than 18 years of experience in the pharmaceutical services industry and has more than 20 years of experience in international trading and management. Prior to China Pioneer Pharma, Mr. Li worked at the Hainan branch of Sumitomo Corporation. Mr. Li graduated from Jianghan Petroleum Normal School with a diploma in English and studied at the China Europe International Business School.

NovaBay also announces that current directors Charles J. Cashion and Tony Wicks have informed the Company’s Board that they will not stand for re-election at the 2015 annual meeting. Following their departures, the Audit Committee will be chaired by Gail Maderis and the Compensation Committee will be chaired by Mr. Sieczkarek. In addition to Mr. Li, Dr. Alex McPherson will stand for re-election to the Board at the 2015 annual meeting of stockholders.

About NovaBay Pharmaceuticals, Inc.: Going Beyond Antibiotics®

NovaBay Pharmaceuticals is a biopharmaceutical company focusing commercializing and developing its non-antibiotic anti-infective products to address the unmet therapeutic needs of the global, topical anti-infective market with its two distinct product categories: the NEUTROX™ Family of Products, including AVENOVA™ for the eye care market and NEUTROPHASE® for wound care, which was initially cleared by FDA, and CELLERX™ for the dermatology market; and its AGANOCIDE® compounds, led by AURICLOSENE™. NovaBay is partnered in the U.S. and around the globe with: PBE, Inc. (USA), IHT, Inc. (USA), Galderma (France), Virbac (France), China Pioneer Pharma (China and Southeast Asia), Shin Poong Pharmaceuticals (South Korea), Biopharm (North African and Middle East), Sarmedic Ltd (Israel) and Alpha Pharma LLC (Ukraine).

Forward-Looking Statements

This press release may contain forward-looking statements, which speak only as of the date of this release and are based on current expectations and involve a number of assumptions. All such forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including future composition of our Board of Directors, descriptions of plans or objectives of its management for future operations, products or services, and forecasts of its revenues, earnings or other measures of economic performance. Forward-looking statements can be identified by the fact that they do not relate strictly to historical or current facts. The Company intends all forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995 and is including this statement for purposes of these safe harbor provisions. More information on our Board and management can be found in our recently filed 10-K. Further, the Company undertake no obligation to update or clarify these forward-looking statements, whether as a result of new information, future events or otherwise.

Stay informed on NovaBay's progress:

Like us on Facebook
Follow us on Twitter
Connect with NovaBay on LinkedIn
Join us on Google+
Visit NovaBay's Website

For NovaBay Avenova purchasing information, please contact:

Toll Free: 1-800-890-0329
www.avenova.com

Contacts

From the Company
NovaBay Pharmaceuticals Inc.
Thomas J. Paulson, 510-899-8809
Chief Financial Officer
Contact Tom
or
Investor Contact
LHA
Jody Cain, 310-691-7100
Jcain@lhai.com

Release Summary

NovaBay announces the appointment of Mark Sieczkarek as Chairman and LI Xinzhou (Paul Li) as director.

Contacts

From the Company
NovaBay Pharmaceuticals Inc.
Thomas J. Paulson, 510-899-8809
Chief Financial Officer
Contact Tom
or
Investor Contact
LHA
Jody Cain, 310-691-7100
Jcain@lhai.com